Scholarlink

Background <p>Insulin glargine Lantus® has been a top 10 Medicare Part D medication by spending for multiple years and was the only glargine until 2015. In 2016, Basaglar®, the first biosimilar referencing Lantus® was released. In 2020, the first biosimilar to achieve FDA-interchangeable designation, Semglee®, became available. This is the first large health-system study of utilization, costs, and savings attributable to alternative glargines.</p> Objective <p>Using the University of California Health Data Warehouse, we assessed utilization, costs, and savings before and after alternative glargines introduction to inform access and policy considerations for patients with diabetes.</p> Design <p>Retrospective, observational, longitudinal study.</p> Patients <p>110 659 glargine users with type I or II diabetes.</p> Main Measures <p>Number and proportion of patients receiving Lantus®, Basaglar®, and Semglee® glargines daily, by age category with spending and savings estimates.</p> Key Results <p>Lantus® user proportion reduction after Basaglar® availability was associated with monthly spending reduction from $191 to $147 for patients under 65 and from $191 to $158 in those 65 and older from January 2015 to January 2022. Glargine users increased from 8 541 to 39 536 from 2012 to 2022. Basaglar® users increased from 6 on January 1st 2017 to 6 010 on January 1st 2022. Semglee® users increased from 29 on January 1st 2021 to 207 on January 1st 2022. Number treated for $100 000 increased after biosimilar availability, from 132 to 171 among patients under 65 and from 124 to 151 among patients 65 and older from 2015 to 2022. Annual savings attributable to biosimilars was $19.05 million in 2022 in the study population.</p> Conclusion <p>Basaglar® release was associated with spending reductions that accelerated after Semglee® availability. Biosimilar availability was associated with increases in glargine users and users per fixed-dollar amount. This study provides supportive evidence for biosimilar adoption policies.</p> Primary Funding Source <p>None.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月4日

查看全文
  • Jonathan H. Watanabe,
  • Michael W. Strand,
  • Weining Shen,
  • Jimmy Kwon,
  • Andrew Reikes

摘要

Background

Insulin glargine Lantus® has been a top 10 Medicare Part D medication by spending for multiple years and was the only glargine until 2015. In 2016, Basaglar®, the first biosimilar referencing Lantus® was released. In 2020, the first biosimilar to achieve FDA-interchangeable designation, Semglee®, became available. This is the first large health-system study of utilization, costs, and savings attributable to alternative glargines.

Objective

Using the University of California Health Data Warehouse, we assessed utilization, costs, and savings before and after alternative glargines introduction to inform access and policy considerations for patients with diabetes.

Design

Retrospective, observational, longitudinal study.

Patients

110 659 glargine users with type I or II diabetes.

Main Measures

Number and proportion of patients receiving Lantus®, Basaglar®, and Semglee® glargines daily, by age category with spending and savings estimates.

Key Results

Lantus® user proportion reduction after Basaglar® availability was associated with monthly spending reduction from $191 to $147 for patients under 65 and from $191 to $158 in those 65 and older from January 2015 to January 2022. Glargine users increased from 8 541 to 39 536 from 2012 to 2022. Basaglar® users increased from 6 on January 1st 2017 to 6 010 on January 1st 2022. Semglee® users increased from 29 on January 1st 2021 to 207 on January 1st 2022. Number treated for $100 000 increased after biosimilar availability, from 132 to 171 among patients under 65 and from 124 to 151 among patients 65 and older from 2015 to 2022. Annual savings attributable to biosimilars was $19.05 million in 2022 in the study population.

Conclusion

Basaglar® release was associated with spending reductions that accelerated after Semglee® availability. Biosimilar availability was associated with increases in glargine users and users per fixed-dollar amount. This study provides supportive evidence for biosimilar adoption policies.

Primary Funding Source

None.